Preview Mode Links will not work in preview mode

This Week in Cardiology

Nov 5, 2021

FFR-guided PCI, ISCHEMIA trial challenged, QFR, and one of the most important studies of 2021 are discussed by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment, visit:

I - FFR-Guided PCI

- FFR-Guided PCI Falls Short vs CABG in Multivessel CAD: FAME 3

- Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery

- The fallacies of fractional flow reserve

II - ISCHEMIA-Trial Challenged

- How Applicable is ISCHEMIA Trial to US Clinical Practice?

- Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population

- The Glass Is at Least Half Full

- Initial Invasive or Conservative Strategy for Stable Coronary Disease


- FAVOR III China: QFR-Guided PCI Shows Advantage Over Angiography

- Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial


- The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life

- Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact